J.P. Morgan Elevates Fresenius as Top Pick in European Medtech After Sector Rout
J.P. Morgan has identified Fresenius SE as its preferred stock in the European medical technology and services sector following a broad market selloff that pushed valuations to levels only seen during the post-global financial crisis recovery. The firm assigns an overweight rating and sees 15-25% upside over 12 months, citing Kabi division momentum…